MONTREAL--(BUSINESS WIRE)--Ability Biologics (“Ability” or “the company”) announced the closing of its $12 million (US) financing round led by founding investor Amplitude Ventures. Amplitude is joined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback